Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (51-60 of 511) with videos related to

Pageof 52
Sort By:
BMC Medicine|April 22, 2017
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Jordi Remon, Benjamin Besse, Jean-Charles Soria
Translational Lung Cancer Research|February 11, 2020
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Translational Lung Cancer Research|May 19, 2020
Cystic brain metastases and <i>RET</i> fusion in lung cancerJordi Remon, Francesco Facchinetti, Benjamin Besse, et al.
Medecine Sciences : M/S|September 14, 2004
[Predicting response to Iressa: unexpected mechanism]Benjamin Besse, Thierry Le Chevalier, Jean-Charles Soria
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2017
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung CancerRoberto Ferrara, Nathalie Auger, Edouard Auclin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2019
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?Roberto Ferrara, Caroline Caramella, Benjamin Besse, et al.
The Lancet. Respiratory Medicine|August 12, 2019
Treatment duration of checkpoint inhibitors for NSCLCJordi Remon, Jessica Menis, Sandrine Aspeslagh, et al.
The European Respiratory Journal|June 2, 2014
Challenges and controversies in thoracic oncology: a new ERJ seriesJean-Paul Sculier, Benjamin Besse, Paul Van Schil
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2019
Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?Jordi Remon, Lizza Hendriks, Sandrine Aspeslagh, et al.
Clinical Case Reports|June 12, 2019
Multiple colic intussusceptionsStylianos Tzedakis, Meredith Flacs, Benjamin Besse, et al.
Pageof 52

Showing results (51-60 of 511) with videos related to

Sort By:
Pageof 52
BMC Medicine|April 22, 2017
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Jordi Remon, Benjamin Besse, Jean-Charles Soria
Translational Lung Cancer Research|February 11, 2020
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Translational Lung Cancer Research|May 19, 2020
Cystic brain metastases and <i>RET</i> fusion in lung cancerJordi Remon, Francesco Facchinetti, Benjamin Besse, et al.
Medecine Sciences : M/S|September 14, 2004
[Predicting response to Iressa: unexpected mechanism]Benjamin Besse, Thierry Le Chevalier, Jean-Charles Soria
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2017
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung CancerRoberto Ferrara, Nathalie Auger, Edouard Auclin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2019
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?Roberto Ferrara, Caroline Caramella, Benjamin Besse, et al.
The Lancet. Respiratory Medicine|August 12, 2019
Treatment duration of checkpoint inhibitors for NSCLCJordi Remon, Jessica Menis, Sandrine Aspeslagh, et al.
The European Respiratory Journal|June 2, 2014
Challenges and controversies in thoracic oncology: a new ERJ seriesJean-Paul Sculier, Benjamin Besse, Paul Van Schil
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2019
Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?Jordi Remon, Lizza Hendriks, Sandrine Aspeslagh, et al.
Clinical Case Reports|June 12, 2019
Multiple colic intussusceptionsStylianos Tzedakis, Meredith Flacs, Benjamin Besse, et al.
Pageof 52